LOGIN  |  REGISTER
Viking Therapeutics
Assertio

Doximity to Participate in Upcoming Investor Events

February 22, 2024 | Last Trade: US$60.08 3.18 -5.03
  • Doximity CFO Anna Bryson to Take Part in Raymond James Institutional Investor Conference and Barclays Global Healthcare Conference

SAN FRANCISCO / Feb 22, 2024 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it will participate in the following upcoming investor events.

Raymond James 45th Annual Institutional Investors Conference
Date: March 5, 2024
Fireside Chat Time: 2:50 pm ET/11:50 am PT
Speaker: Anna Bryson, Chief Financial Officer

Barclays 26th Annual Global Healthcare Conference
Date: March 13, 2024
Fireside Chat Time: 11:15 am ET/8:15 am PT
Speaker: Anna Bryson, Chief Financial Officer

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page